According to a news release, the services will be provided for RetinalGeniX Technologies’ Institutional Review Board to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration.
RetinalGeniX Technologies Inc announced it has contracted with MEDsan Inc to provide diagnostic testing services for its Institutional Review Board (IRB) to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration.
“We are pleased to extend our services into testing for wet macular degeneration, a field that we have been looking at for quite some time,” . Jonathan Brenner, PhD, CEO of MEDsan Inc., said in a news release.1 “We feel that RetinalGeniX is the right partner to start this venture with.”
Moreover, according to the news release, RetinalGeniX also has started planning its pharmaceutical clinical studies for treating dry age-related macular degeneration (AMD) and Alzheimer’s/dementia complex studies as part of its DNA/RNA GPS initiative.
According to the news release, RetinalGeniX has also filed two provisional patents related to these studies and formed an institutional review board to launch a 390-patient clinical study intended to validate the relative suitability of anti-VEGF ocular injection treatments for patient candidates with wet AMD.
In concert with its pharmaco-genetic mapping, the company is developing a high-resolution retinal home and remote monitoring system that is intended to offer 24/7 real-time alerts to both physicians and patients and that does not require dilation of the pupil. The technology is intended to prevent blindness through the early detection and treatment of ocular diseases and also to detect initial physiological changes that could indicate possible future systemic disease including neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions.1
“MEDsan is a next-generation diagnostic CLIA-approved laboratory services facility equipped with the most technically advanced diagnostic equipment in the pharmaco-genetic space,” Jerry Katzman, MD, chairman, president and CEO of RetinalGeniX, said in the news release.
Katzman added in the news release Jonathan Brenner, PhD, and his team are specialists running diagnostic panels and dovetails RetinalGeniX’s clinical agenda to clinical study requirements.
“It's a perfect match,” he concluded in the news release. “We look forward to working with MEDsan on this strategic venture.”